Printer Friendly

LIFECORE BIOMEDICAL REPORTS FISCAL 1992 RESULTS

 LIFECORE BIOMEDICAL REPORTS FISCAL 1992 RESULTS
 CHASKA, Minn., Sept. 3 /PRNewswire/ -- Lifecore Biomedical, Inc.


(NASDAQ: LCBM) today reported net sales of $4,482,000 for the fiscal year ended June 30, 1992, a decrease of $1,402,000 or 24 percent over last year. The company also reported a net loss for the current year of $5,303,000 or $.81 per share, compared to a net loss of $2,569,000 or $.49 per share for the previous year.
 The sales decrease was primarily attributable to reduced hyaluronate purchases by Alcon Surgical, Inc. Lifecore's hyaluronate supply agreement with Alcon did not allow for a scheduled shipment during the second quarter. Subsequently, Lifecore and Alcon have agreed to a new supply agreement which extends shipments through Dec. 31, 1995.
 The net loss for the year reflects the decrease in sales as well as an increase in operating expenses. The rise in operating expenses reflects expanded sales and marketing activities related to the company's oral restorative products. In addition, research and development expenses increased as a result of both the continuing human clinical trials on the Sustain(R) Dental Implant System and production development activities designed to enhance the company's hyaluronate manufacturing process technology. Similarly, additional expenses were related to establishing the increased manufacturing capability at Lifecore's new Chaska facility. The installation and validation of the new hyaluronate manufacturing equipment, a major component of the current activity, is proceeding on schedule.
 The loss for fiscal 1992 was within management's expectations and is indicative of the extensive investment that Lifecore is making in its manufacturing and marketing capabilities.
 Lifecore develops, manufactures and markets sterile medical devices for a variety of surgical applications, through both direct sales and OEM supplier relationships.
 LIFECORE BIOMEDICAL, INC.
 Statements of Operations
 (In thousands, except per share amounts)
 6/30/92 6/30/91
 Net sales $4,482 $5,884
 Cost of goods sold 3,429 3,536
 Gross profit 1,053 2,348
 Operating expenses
 Research and development 1,555 622
 Marketing and sales 2,592 1,853
 General and administrative 1,540 1,276
 Write down of building and equip. -- 1,200
 Manufacturing relocation 714 --
 -- 6,401 4,951
 Earnings (loss) from operations (5,348) (2,603)
 Other income (expense)
 Interest expense (780) (30)
 Interest income 825 64
 -- 45 34
 Net loss $(5,303) $(2,569)
 Net loss per common share $(.81) $(.49)
 Weighted average shares
 outstanding 6,538,972 5,226,867
 CONDENSED BALANCE SHEETS
 (In thousands)
 6/30/92 6/30/91
 ASSETS
 Current assets
 Cash and short-term investments $10,816 $2,352
 Accounts receivable 953 1,462
 Inventories 2,335 1,599
 Other 472 286
 -- 14,576 5,699
 Property, plant and equipment, net 9,001 9,163
 Other assets
 Intangibles 2,588 114
 Security deposits 904 83
 Other 738 685
 -- 4,230 882
 -- $27,807 $15,744
 LIABILITIES AND SHAREHOLDERS' EQUITY
 Current liabilities $4,642 $3,496
 Long-term debt 8,136 7,748
 Shareholders' equity 15,029 4,500
 -- $27,807 $15,744
 -0- 9/3/92
 /CONTACT: John C. Heinmiller or James W. Bracke, 612-368-4300, both of Lifecore Biomedical/
 (LCBM) CO: Lifecore Biomedical, Inc. ST: Minnesota IN: MTC SU: ERN


AL -- MN004 -- 6374 09/03/92 11:32 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 3, 1992
Words:538
Previous Article:TRIPLE THREAT ENTERPRISES TO CHANGE NAME TO GAMING DEVICES
Next Article:SCIENTIFIC SOFTWARE SIGNS LETTER OF INTENT WITH RENAISSANCE CAPITAL GROUP
Topics:


Related Articles
LIFECORE BIOMEDICAL ANNOUNCES FIRST QUARTER RESULTS
LIFECORE REPORTS SECOND QUARTER RESULTS; POTENTIAL CONTRACT RENEWAL
LIFECORE BIOMEDICAL REPORTS THIRD QUARTER RESULTS
LIFECORE BIOMEDICAL REPORTS FISCAL 1992 RESULTS
LIFECORE BIOMEDICAL REPORTS FIRST QUARTER RESULTS; INCREASED ALCON ORDER
LIFECORE REPORTS RECORD SECOND QUARTER RESULTS
LIFECORE REPORTS RECORD THIRD QUARTER REVENUES
LIFECORE REPORTS FIRST QUARTER FISCAL 1996 FINANCIAL RESULTS
Lifecore Reports First Fiscal Quarter Results
Lifecore Reports Second Fiscal Quarter Results

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters